Shionogi & Co., Ltd.
塩野義製薬株式会社
TypePublic (K.K)
TYO: 4507
Nikkei 225 Component
IndustryBiotechnology & Pharmaceuticals
FoundedOsaka, Japan (March 17, 1878 (1878-03-17))
FounderGisaburo Shiono Sr.
Headquarters1-8, Doshomachi 3-chome, Chuo-ku, Osaka 541-0045, Japan
Key people
Products
RevenueIncrease $ 3.009 billion USD (FY 2012)
(¥ 282.904 billion JPY) (FY 2012)
Increase $709.79 million USD (FY 2012)
(¥ 66.728 billion JPY) (FY 2012)
Number of employees
Consolidated : 6,082
WebsiteOfficial website
Footnotes / references
[1][2]

Shionogi & Company, Limited (塩野義製薬株式会社, Shionogi Seiyaku Kabushiki Kaisha) is a Japanese pharmaceutical company best known for developing Crestor. Medical supply and brand name also uses katakana (シオノギ).

Shionogi has business roots that date back to 1878, and was incorporated in 1919. Among the medicines produced are for hyperlipidaemia, antibiotics, and cancer medicines.

In Japan it is particularly known as a producer of antimicrobial and antibiotics. Because of antibiotic resistance and slow growth of the antibiotic market, it has teamed up with US based Schering-Plough (merged in 2009 with Merck & Co) to become a sole marketing agent for its products in Japan.

Shionogi had supported the initial formation of Ranbaxy Pharmaceuticals, a generic manufacturer based in India. In 2012 the company became a partial owner of ViiV Healthcare, a pharmaceutical company specialising in the development of therapies for HIV.[3]

The company is listed on the Tokyo Stock Exchange and Osaka Securities Exchange and is constituent of the Nikkei 225 stock index.[4]

Medicines

Released

Under development

Media

References

  1. ^ "Shionogi Company Profile". Archived from the original on 28 January 2020. Retrieved 18 March 2014.
  2. ^ "Shionogi Annual Report 2013" (PDF). Archived (PDF) from the original on 11 July 2019. Retrieved 18 March 2014.
  3. ^ "Shionogi and ViiV Healthcare announce new agreement to commercialise and develop integrase inhibitor portfolio". viivhealthcare.com. Archived from the original on 7 March 2014. Retrieved 18 March 2014.
  4. ^ "Components:Nikkei Stock Average". Nikkei Inc. Archived from the original on 14 November 2016. Retrieved 11 March 2014.
  5. ^ Du, Lisa (7 October 2021). "Covid Pill Sales Could Hit $2 Billion, Japan's Shionogi Says". Bloomberg. Retrieved 21 March 2022.
  6. ^ Du, Lisa (22 February 2010). "AstraZeneca begins court fight over Crestor patent". Reuters. Retrieved 21 March 2022.
  7. ^ "Duchesnay acquires Osphena from Shionogi Inc" (Press release). Duchesnay. 10 March 2017. Archived from the original on 24 October 2019. Retrieved 23 October 2019.
  8. ^ "Japan's Shionogi seeks approval for COVID-19 pill". Reuters. Reuters. 25 February 2022.
  9. ^ "Notice regarding an initiation of Phase 2 clinical trial by BioAge aimed at treating older patients of COVID-19" (PDF) (Press release). Retrieved 21 March 2022.
  10. ^ "Study to Evaluate the Safety, Tolerability, and Efficacy of BGE-175 in Hospitalized Adults With Coronavirus Disease 2019 (COVID-19) That Are Not in Respiratory Failure". ClinicalTrials.gov. Retrieved 21 March 2022.
  11. ^ Wong, Lok-Yin (21 March 2022). "Eicosanoid signaling blockade protects middle-aged mice from severe COVID-19". Nature.
  12. ^ Swift, Rocky (26 January 2021). "Japan's Shionogi sells coronavirus drug rights to U.S. biotech BioAge".
  13. ^ "New BioAge Drug Prevents Death From COVID-19 in Old Mice by Reversing Immune Aging" (Press release). BioAge Labs. SciTech (magazine). Retrieved 21 March 2022.
  14. ^ Perry, Alan. "Sponsor Company Profiles". Archived from the original on 17 June 2013. Retrieved 25 April 2012.